CONMED (CNMD) Beats Q2 2026 EPS by 24% and Raises Full-Year Guidance
As seen on the 24/7 Wall St. homepage on July 29, 2026.
CONMED crushed expectations with a 24% EPS beat as portfolio optimization and international growth offset a planned exit from gastroenterology. The company raised full-year guidance to $4.48 to $4.60 per share, now expecting 5% to 6% organic constant currency sales growth.
Continue ReadingShow less
CONMED reported Q2 2026 earnings per share of $1.38, well ahead of the $1.11 consensus estimate for a beat of roughly 24%. Revenue came in at $343.5 million, topping estimates of $337.5 million by about 1.8%. The quarter marked one of the strongest beats in the company's recent history, with portfolio optimization and international growth cited as key contributors alongside a planned exit from gastroenterology.
The gastroenterology exit is a deliberate strategic move rather than a surprise headwind, and management appears confident that the remaining portfolio can more than compensate. That confidence is reflected in the raised full-year guidance, which now calls for earnings of $4.48 to $4.60 per share and organic constant currency sales growth of 5% to 6%.
Sponsored
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
CONMED's EPS trend over the past several quarters shows a consistent pattern of beating estimates, with reported figures coming in above consensus every period from Q3 2024 through Q2 2026. Investors will be watching whether the gastroenterology wind-down creates any near-term revenue drag in the back half of the year, and whether international momentum is enough to keep the raised guidance range intact.
Mentioned: CNMD